KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

Acute Myeloid Leukemia Clinical Trial

Official title:

The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children With ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02646839
• Other study ID #: PBMTC ONC1401
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: October 2015
• Est. completion date: August 2024

Study information

• Verified date: October 2023
• Source: Children's Hospital Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II, open-label, non-randomized, prospective study of haploidentical transplantation using KIR-favorable donors for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The relationship of KIR2DL1 polymorphisms to survival in children with these diseases undergoing any approach to allogeneic HCT during the study time frame will also be determined.

Description:

Allogeneic hematopoietic stem cell transplantation (HCT) using matched related and unrelated donors is well-accepted therapy for children with subtypes of high-risk acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). For the 40-50% of children who do not have matched donors available, HCT approaches have varied by center and regional preferences. HCT physicians in France and North America tend to use human leukocyte antigen (HLA)-mismatched umbilical cord blood (UCB), while those in many large centers in Germany, parts of Asia, and selected US centers favor HLA-haploidentical donors. Both approaches have improved significantly through the years for a variety of reasons, including better supportive care, cell processing techniques that now deliver more consistently high-quality products, understanding of the importance of cell dose, and key modifications of preparative and immunosuppressive regimens.

Both stem cell sources offer distinct advantages and disadvantages. T-cell-depleted haploidentical approaches with killer-cell immunoglobulin-like receptor (KIR) mismatches have been shown to lead to less relapse in patients with AML13 and, in some studies, children with ALL as well. Disadvantages to this approach have been vulnerability to viral infection and the requirement for an ex vivo T-cell depletion procedure that is currently under IND. Cord blood is readily available and is permissive of some degree of HLA mismatch, but current studies show no advantage in survival compared with matched unrelated donors. Recently, a randomized study of one vs. two UCB units based on a hypothesis of decreased relapse incidence with two units resulted in equivalent outcomes in both arms. Neutrophil engraftment and immune recovery after UCB transplantation is relatively slow, leading to a higher risk of transplant-related mortality; in addition, larger patients require two cord units, dramatically increasing the cost of stem cell procurement. No direct comparisons of these two stem cell sources (haploidentical vs. UCB) have been performed in pediatric patients.

Recently, investigators at St. Jude Children's Research Hospital published excellent outcomes using haploidentical donors with grafts depleted for CD3+ cells by an ex vivo Miltenyi CliniMACS system. Their recent cohort of AML and ALL patients treated without total body irradiation (TBI) had a 5-year survival of 88±15% in 19 consecutive patients, with 17 surviving long-term and disease-free and only 2 patients died of progressive leukemia. These results compared favorably with the 5-year survival of 70±38% for transplantations using matched siblings and 61±17% for matched unrelated donors treated with identical leukemia protocols with indications for transplantation defined a priori. These preliminary results suggest that a strategy of using favorable KIR-mismatched haploidentical transplantation may lead to a better outcome than other alternative donor approaches without the side effects of TBI. This protocol is a phase II trial seeking to establish the feasibility and preliminary outcomes with this approach in a multi-institutional setting.

In addition to KIR-HLA matching, KIR allele polymorphism may also affect transplant outcomes.Recent data from St. Jude showed that in 312 pediatric HCTs, the patients who received a donor graft containing the functionally stronger KIR2DL1 allele with arginine at amino acid position 245 (KIR2DL1-R245) had better survival (p=0.0028) and a lower relapse rate (p=0.022) than those who received a donor graft that contained only the functionally weaker KIR2DL1 allele with cysteine at the same position (KIR2DL1-C245). Patients who received a KIR2DL1-R245-positive graft with an HLA-C receptor-ligand mismatch had the best survival (p=0.00004) and lowest risk of leukemia relapse (p=0.005). Thus, both KIR-HLA matching and KIR allele polymorphism have prognostic value. We will attempt to prospectively confirm these results in this multicenter trial.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 50
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

2.3.1 Inclusion Criteria for the Biology (KIR2DL1 Polymorphisms/ALL MRD), Comparative Outcomes, and Cost Effectiveness Trial

1. Any patient with ALL, AML, or MDS who is deemed eligible for and undergoes HCT at participating centers who provides consent for the KIR2DL1 polymorphisms, comparative outcomes and cost-effectiveness portion of the trial.

2. Any ALL patient undergoing allogeneic HCT at participating centers is eligible for the ALL deep sequence MRD portion of the trial.

3. Patients ineligible for the KIR-favorable haploidentical phase II trial who require T-cell depletion may be treated using TCR aß+CD3+/CD19+ cell depletion. These patients will be followed descriptively on this portion of the trial. Preparative regimen will be at the discretion of the transplant center, but the options associated with this protocol are recommended.

2.3.2 Inclusion Criteria for the KIR-favorable Haploidentical Phase II trial:

1. Age < 22 years

2. Disease and disease status:

• ALL high-risk in first remission (<5% blasts by morphology pre-transplant) meeting criteria for transplant. Example CR1 indications: induction failure (>5% blasts by morphology on post-induction BM), minimal residual disease greater than or equal to 1% marrow blasts by morphology after induction, minimal residual disease by flow cytometry >0.01% after consolidation, hypodiploidy (<44 chromosomes), persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission (e.g. persistent molecular BCR-ABL positivity).

• ALL in second remission: B-cell; early (less than or equal to 36 months from initiation of therapy) BM relapse, late BM relapse with MRD >0.1% by flow cytometry after first induction therapy; T-cell or Ph+ with BM relapse at any time; very early (less than 18 months from initiation of therapy) isolated extramedullary relapse (T or B-cell)

• Myelodysplastic syndrome (MDS): Any 2001 WHO classification subtype (Appendix I). RAEB-2 patients may proceed directly to transplant, but may also receive induction chemotherapy before transplant. Patients with =20% morphologic marrow blasts will require induction therapy to reduce morphologic marrow blasts below 5% before transplant.

• High-risk AML defined as monosomy 5, del 5q, monosomy 7, M6, M7, t(6;9), FLT3-ITD, or patients who have greater than or equal to 25% blasts by morphology after induction, or who do not achieve CR after 2 courses of therapy. Also, patients with = 0.1% MRD or evidence of progressive extramedullary disease after induction chemotherapy.

• AML in second or subsequent morphologic remission.

3. Has not received a prior allogeneic hematopoietic stem cell transplant.

4. Does not have a suitable HLA-matched sibling donor available for stem cell donation.

5. Does not have a suitable matched or single antigen mismatched related or unrelated donor available at any time (noted by search), or it is in the patient's best interest as judged by the attending to move forward with stem cell transplantation rather than wait for an unrelated donor to become available (refer to subsection 2.5.1 for further details).

6. Has a suitable HLA KIR favorable haploidentical matched family member available for stem cell donation.

7. Karnofsky Index or Lansky Play-Performance Scale = 60 % on pre-transplant evaluation. Karnofsky scores must be used for patients > 16 years of age and Lansky scores for patients < 16 years of age.

8. Able to give informed consent if > 18 years, or with a legal guardian capable of giving informed consent if < 18 years.

9. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:

• Pulmonary: FEV1, FVC, and corrected DLCO must all be = 50% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.

• Renal: Creatinine clearance or radioisotope GFR ³ 70 mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:

Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

= 16 years 1.7 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the CDC.45

• Cardiac: Shortening fraction of = 27% by echocardiogram or radionuclide scan (MUGA) or ejection fraction of = 50% by echocardiogram or radionuclide scan (MUGA), choice of test according to local standard of care.

• Hepatic: \SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome.

Exclusion Criteria:

1. Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants.

2. Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded. Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation.

3. Patients with active CNS leukemia or any other active site of extramedullary disease at the time of enrollment are not permitted. Note: Those with prior history of CNS or extramedullary disease, but with no active disease at the time of pre-transplant workup, are eligible.

4. Patients with genetic disorders (generally marrow failure syndromes) prone to secondary AML/ALL with known poor outcome are not eligible (Fanconi Anemia, Kostmann Syndrome, Dyskeratosis Congenita, etc).

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Leukemia
• Leukemia, Lymphoid
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia

Intervention

Device:
• CliniMacs TCR alpha-beta-Biotin system
Graft ex vivo depleted of T cell receptor (TCR) aß+CD3+/CD19+ cells

Locations

Country	Name	City	State
United States	Lurie Children's Hospital	Chicago	Illinois
United States	Children's Hospital Los Angeles	Los Angeles	California
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Vanderbilt University - Monroe Carell Jr. Children's Hospital	Nashville	Tennessee
United States	Children's Hospital Oakland	Oakland	California
United States	Stanford University Medical Center	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Rady Children's Hospital	San Diego	California
United States	University of California, San Francisco	San Francisco	California
United States	New York Medical Center	Valhalla	New York

Sponsors (9)

Lead Sponsor	Collaborator
Michael Pulsipher, MD	Ann & Robert H Lurie Children's Hospital of Chicago, Children's Hospital of Philadelphia, Medical College of Wisconsin, New York Medical College, Rady Children's Hospital, San Diego, UCSF Benioff Children's Hospital Oakland, University of California, San Francisco, Vanderbilt University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease free survival at 1 year post HCT		1 year
Primary	1 yr disease free survival of patients transplanted with donors homozygous for KIR2DL1-C245 will be compared to patients with donors hetero- or homozygous for KIRD2DL1-R245 polymorphisms		1 year
Secondary	1- and 2-year overall survival (OS) for children undergoing TCR aß+CD3+/CD19+ cell depleted favorably KIR-mismatched haplo-HCT		2 years
Secondary	Cumulative incidence of neutrophil and platelet engraftment, primary and secondary rejection, NTM, and relapse in KIR favorable haplo-HCT recipients		1 year
Secondary	Cumulative incidence of overall grades II-IV and III-IV acute GVHD in KIR favorable haplo-HCT recipients		5 years
Secondary	Compare the 2-year DFS and OS of patients transplanted using favorably KIR-mismatched haplo-HCT with other ALL, AML, and MDS patients concurrently transplanted using other approaches at the participating centers.		1 year
Secondary	Compare the 2-year DFS and OS of patients transplanted using favorably KIR-mismatched haplo-HCT with other ALL, AML, and MDS patients concurrently transplanted using 4/6 and 5/6 HLA-matched cord blood reported to the CIBMTR		1 year
Secondary	Test sensitivity of flow cytometry MRD for all patients; in ALL patients, compare flow cytometry MRD with IgH and TCR next-generation-sequencing (NGS) MRD pre- and post-HCT for predicting relapse, DFS, and OS in children undergoing allog-HCT.		1 year
Secondary	To compare costs of transplantation using favorably KIR-mismatched haplo-HCT with patients receiving alternative donor transplantation at centers participating in the trial		1 year
Secondary	1- and 2-year event free survival (DFS) for children undergoing TCR aß+CD3+/CD19+ cell depleted favorably KIR-mismatched haplo-HCT		2 years
Secondary	Cumulative incidence of chronic GVHD in KIR favorable haplo-HCT recipients.		1 year
Secondary	Cumulative incidence of mild, moderate, and severe cGVHD		1 year